Segment reporting (Tables)

6 Months Ended

Jan. 31, 2018

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended January 31, 2018	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	19,530			—			—			—		$	19,530
Product revenues		—		$	7,122			—			—			7,122
Royalty and license fee income		—			300			—			—			300
		19,530			7,422			—			—			26,952
Operating costs and expenses:
Cost of clinical laboratory services		11,730			—			—			—			11,730
Cost of product revenues		—			3,877			—			—			3,877
Research and development		—			591		$	221			—			812
Selling, general and administrative		6,107			2,899			—		$	2,064			11,070
Provision for uncollectible accounts receivable		800			(21	)		—			—			779
Legal fee expense		8			25			—			1,667			1,700
Total operating costs and expenses		18,645			7,371			221			3,731			29,968
Operating income (loss)		885			51			(221	)		(3,731	)		(3,016	)
Other income (expense):
Interest		(23	)		11			—			197			185
Other		3			1			—			29			33
Foreign exchange gain		—			800			—			—			800
Income (loss) before income taxes	$	865		$	863		$	(221	)	$	(3,505	)	$	(1,998	)
Depreciation and amortization included above	$	413		$	355		$	—		$	18		$	786
Share-based compensation included in above:
Selling, general and administrative		28		$	21			—		$	159			208
Total	$	28		$	21		$	—		$	159		$	208
Capital expenditures	$	576		$	28		$	—		$	—		$	604

Three months ended January 31, 2017	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	18,837			—			—			—		$	18,837
Product revenues		—		$	6,983			—			—			6,983
Royalty and license fee income		—			440			—			—			440
		18,837			7,423			—			—			26,260
Operating costs and expenses:
Cost of clinical laboratory services		11,052			—			—			—			11,052
Cost of product revenues		—			3,520			—			—			3,520
Research and development		—			516		$	(33	)		—			483
Selling, general and administrative		5,897			2,905			—		$	2,416			11,218
Provision for uncollectible accounts receivable		594			85			—			—			679
Legal fee expense		49			16			—			305			370
Total operating costs and expenses		17,592			7,042			(33	)		2,721			27,322
Operating income (loss)		1,245			381			33			(2,721	)		(1,062	)
Other income (expense):
Interest		(28	)		12			—			95			79
Other		17			—			—			7			24
Foreign exchange loss		—			(94	)		—			—			(94	)
Income (loss) before income taxes	$	1,234		$	299		$	33		$	(2,619	)	$	(1,053	)
Depreciation and amortization included above	$	394		$	501		$	—		$	20		$	915
Share-based compensation included in above:
Cost of clinical laboratory services	$	1			—			—			—		$	1
Selling, general and administrative		23		$	15			—		$	202			240
Total	$	24		$	15		$	—		$	202		$	241
Capital expenditures	$	175		$	—		$	—		$	—		$	175

Six months ended January 31, 2018	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	39,864			—			—			—		$	39,864
Product revenues		—		$	14,203			—			—			14,203
Royalty and license fee income		—			561			—			—			561
		39,864			14,764			—			—			54,628
Operating costs and expenses:
Cost of clinical laboratory services		23,772			—			—			—			23,772
Cost of product revenues		—			7,266			—			—			7,266
Research and development		—			1,114		$	445			—			1,559
Selling, general and administrative		12,202			5,513			—		$	4,246			21,961
Provision for uncollectible accounts receivable		1,600			(7	)		—			—			1,593
Legal fee expense		21			28			—			2,082			2,131
Total operating costs and expenses		37,595			13,914			445			6,328			58,282
Operating income (loss)		2,269			850			(445	)		(6,328	)		(3,654	)
Other income (expense):
Interest		(48	)		23			—			367			342
Other		17			8			—			44			69
Foreign exchange gain		—			605			—			—			605
Income (loss) before income taxes	$	2,238		$	1,486		$	(445	)	$	(5,917	)	$	(2,638	)
Depreciation and amortization included above	$	817		$	681		$	—		$	37		$	1,535
Share-based compensation included in above:
Selling, general and administrative		60		$	44			—		$	309			413
Total	$	60		$	44		$	—		$	309		$	413
Capital expenditures	$	994		$	72		$	—		$	—		$	1,066

Six months ended January 31, 2017	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	37,395			—			—			—		$	37,395
Product revenues		—		$	14,409			—			—			14,409
Royalty and license fee income		—			740			—			—			740
		37,395			15,149			—			—			52,544
Operating costs and expenses:
Cost of clinical laboratory services		21,948			—			—			—			21,948
Cost of product revenues		—			6,829			—			—			6,829
Research and development		—			1,143		$	162			—			1,305
Selling, general and administrative		11,849			5,851			—		$	5,012			22,712
Provision for uncollectible accounts receivable		1,260			88			—			—			1,348
Legal fee expense		101			28			—			613			742
Total operating costs and expenses		35,158			13,939			162			5,625			54,884
Operating income (loss)		2,237			1,210			(162	)		(5,625	)		(2,340	)
Other income (expense):
Interest		(57	)		22			—			160			125
Other		119			—			—			24			143
Foreign exchange loss		—			(455	)		—			—			(455	)
Income (loss) before income taxes	$	2,299		$	777		$	(162	)	$	(5,441	)	$	(2,527	)
Depreciation and amortization included above	$	795		$	1,009		$	—		$	38		$	1,842
Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Selling, general and administrative		40		$	26			—		$	323			389
Total	$	43		$	26		$	—		$	323		$	392
Capital expenditures	$	587		$	102		$	—		$	—		$	689